The medication is widely used for symptomatic relief in acute episodes of throat discomfort. This product is applied in contexts where additional symptomatic support is needed, primarily helping to address symptoms related to physical discomfort in the throat. This includes the localized soreness and pain often associated with acute or episodic changes. This product is generally considered relevant for the short-term management of sore throat symptoms.

This medicine is applied in addressing the cluster of symptoms related to soreness, localized pain, swelling, and irritation. It is commonly used when symptoms intensify, and supportive relief is needed during conditions associated with acute or disruptive episodes.

“Applied across domains where additional symptomatic support is needed.”

The product provides supportive relief when symptoms interfere with routine activities, which contributes to easing the overall symptom load. It is relevant for easing discomfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Focus on Physical Discomfort

---

Regulatory References

1. European Commission Public Health Register

Strefen (flurbiprofen lozenges) is an anti-inflammatory medicine with official eligibility restrictions based on age, medical history, and physiological status.

Eligibility Rules

Category	Eligibility Status (Official Labeling)
Age Group	Allowed for adults and adolescents 12 years of age and older. Not indicated for children under 12 years.
Pregnancy	Contraindicated during the last trimester. Not recommended during the first six months or for women attempting to conceive.
Breastfeeding	Not recommended for use.

Absolute Contraindications

The medicine must not be used by individuals with the following conditions, as stated in regulatory documents:

• Hypersensitivity or Allergy: A known allergy to flurbiprofen or a history of allergic reactions (like asthma or hives) to aspirin or other NSAIDs.
• Active GI Disease: An active or history of recurrent peptic ulcer/gastrointestinal haemorrhage or perforation.
• Severe Organ Failure: Diagnosed severe heart failure, severe renal failure, or severe hepatic failure.

Use requires special caution for patients with a history of hypertension, heart failure, kidney/liver impairment, asthma, or inflammatory bowel diseases (e.g., Crohn's disease or ulcerative colitis).

The regulatory profile for Flurbiprofen (Strefen) lozenges details specific official interaction patterns, which primarily involve pharmacokinetic modifications, pharmacodynamic reinforcement of adverse effects, and mandatory timing rules. These documented statements strictly define constraints for co-administration with other medicines and substances.

Interaction Restrictions and Avoidance

Category	Interaction Requirement (Regulatory Statement)
NSAIDs and Anti-platelets	Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or acetylsalicylic acid should be avoided due to the increased risk of gastrointestinal bleeding and ulceration.
Oral Corticosteroids	Concomitant use increases the risk of gastrointestinal ulceration and haemorrhage.
Alcohol	Concurrent use may increase the overall risk of adverse reactions, particularly bleeding in the gastrointestinal tract.

Pharmacokinetic and Timing Constraints

Flurbiprofen may alter the systemic exposure of co-administered agents. The medicine may increase the plasma levels of Lithium and Phenytoin, requiring plasma concentration monitoring. Similarly, administration may lead to elevated concentrations and increased toxic effect of Methotrexate. The use of Flurbiprofen with Anticoagulants (e.g., Warfarin) may enhance the effects of the anticoagulant.

Specific timing rules apply to certain combinations:

• Mifepristone: Must not be used for 8 to 12 days following administration.
• Methotrexate: Avoid co-administration within 24 hours before or after use.

The profile also notes that the use of Flurbiprofen with Antihypertensive medicines may result in a reduction of the Antihypertensive effect. A distinct caution is associated with patients with compromised renal function, where co-administration with Diuretics or ACE Inhibitors carries a heightened risk of acute renal failure.

Enzyme Inhibition and Eicosanoid Pathway Modulation

The action of Flurbiprofen begins at the molecular level with the competitive inhibition of Cyclooxygenase (COX) enzymes, primarily the inducible COX-2 isoform, which catalyze the synthesis of Prostaglandins ( PGE2). By blocking this enzymatic step, the drug directly suppresses the production of chemical mediators which act in inflammatory processes.

Attenuation of Peripheral Pain Sensitization

The resulting drop in local Prostaglandin levels leads to a distinct physiological consequence: it reduces the chemical sensitization of the peripheral nociceptors (pain-sensing nerve endings) located in the pharyngeal tissues. This action results in decreased excitability of the sensory nerves and raises the threshold for nociceptive signaling, contributing to the attenuation of peripheral nociceptive activation.

Localized Anti-Inflammatory Response

This mechanism modulates the acute inflammatory response by reducing the effects of Prostaglandins on the local vasculature. By countering the action of these mediators, Flurbiprofen limits increased capillary permeability and local blood vessel dilation, thereby leading to the inhibition of local edema formation.

How to Use Strefen

Strefen, which contains the active ingredient Flurbiprofen 8.75 mg, is designed for the short-term symptomatic relief of sore throat. The medicine is approved for oromucosal administration, meaning it is applied locally to the mouth and throat tissues.

Official Dosing and Administration

The following schedules reflect the standards for dosing and administration.

Form	Single Dose	Dosing Interval	Maximum Daily Limit
Lozenge	1 lozenge (8.75 mg)	Every 3 to 6 hours as needed	5 lozenges (43.75 mg total)
Spray	3 actuations (8.75 mg)	Every 3 to 6 hours as needed	5 doses (15 actuations)

Administration Conditions and Duration

Duration of Use: The product is for short-term use only, for a maximum period of three days. The lowest effective dose should be used for the shortest duration necessary.

Lozenge Instructions: To avoid local irritation, the lozenge must be sucked slowly and should be moved around the mouth during the process.

Spray Instructions: Before first use, or after a prolonged period of inactivity, the pump must be primed (actuated at least four times) until a consistent mist is produced. Users must not inhale while administering the spray to the back of the throat.

Population-Specific Rules

Age Restrictions: The lozenge is not indicated for children under 12 years of age. The oromucosal spray is not indicated for individuals under 18 years of age. No dose reduction is typically required for patients with mild to moderate renal or hepatic impairment.

Flurbiprofen 8.75 mg: Clinical Evidence Summary

---

Clinical research primarily focuses on the local, low-dose flurbiprofen (8.75 mg) formulations, such as lozenges and oromucosal sprays, for the short-term relief of sore throat symptoms associated with upper respiratory tract infections.

Efficacy in Symptom Relief

Multiple randomized, double-blind, placebo-controlled trials have investigated the effects of flurbiprofen 8.75 mg on pharyngeal symptoms. Study findings consistently indicate greater patient-reported relief compared to placebo across several key metrics:

• Throat Soreness: Significant reductions in pain intensity have been reported in various trials. Some studies suggest relief can be detected as early as 15 to 30 minutes after administration.
• Swallowing Difficulty: Research has also evaluated changes in the difficulty of swallowing, finding that the active treatment group reported greater improvement than the placebo group over the assessment period.
• Sensation of Swollen Throat: Trials have measured the patient's subjective feeling of a swollen throat, with results showing differences in reported relief compared to placebo over a few hours.

Trial Safety Reporting

The formulation has generally been assessed as well-tolerated in clinical trials involving the low 8.75 mg dose, with most adverse events being mild and transient. The most frequently noted side effects in these studies were gastrointestinal discomfort and taste perversion, the rates of which were often similar to those observed in the placebo groups. Localized formulations aim to achieve a high concentration of the drug at the site of inflammation in the throat, allowing for a lower systemic dose than is used for conditions like arthritis.

Key Studies & References

1. Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial
2. Sore throat (acute): antimicrobial prescribing (NG84) - NICE Guideline
3. Flurbiprofen Geiser - EMEA-H-A-29(4)-1487 - Annex I-II-III (Regulatory Assessment for Flurbiprofen)

Common questions about Strefen (FAQ)

Q: What is the difference between Strefen and other common sore throat lozenges?

Official product information indicates that Strefen contains the active ingredient Flurbiprofen, which is classified as a non-steroidal anti-inflammatory drug (NSAID). This is a key difference, as Flurbiprofen works by targeting inflammation and pain in the throat, distinguishing it from lozenges that rely only on antiseptic or anesthetic ingredients.

Q: Is Strefen only used for throat pain or can it help with ear pain too?

According to the official regulatory documents, the lozenge is indicated for the short-term symptomatic relief of sore throat symptoms, specifically localized to the throat. Clinical trials and evidence primarily assess its effectiveness on pharyngeal symptoms, such as throat soreness and difficulty swallowing.

Q: Is an allergic reaction to Strefen common, and what are the signs?

Hypersensitivity (allergic) reactions are reported as possible effects. Official documents state that signs of a serious reaction can include swelling of the face, tongue, or throat, or severe rash and blistering. If signs of a severe allergic reaction are observed, professional medical intervention is required.

Q: Can people with high blood pressure use Strefen?

Official product warnings indicate that caution is advised for individuals with a history of high blood pressure (hypertension). This caution is in place because, as an NSAID, the active ingredient may contribute to fluid retention or an increase in blood pressure levels.

Q: Why is Strefen often mentioned in discussions about tonsillitis pain?

The medicine is intended for the symptomatic relief of pain associated with localized oropharyngeal inflammation. Clinical data from studies examining the lozenge's effects have often included adult participants diagnosed with conditions such as tonsillo-pharyngitis (inflammation of the tonsils and pharynx).

Q: Are there any food or drink items that should be avoided when using Strefen?

The official warnings for Flurbiprofen state that co-administration with alcohol is generally not recommended due to an increased risk of adverse reactions, particularly bleeding in the gastrointestinal tract.

Q: Why does Strefen lozenge sometimes cause a slight burning sensation?

A common local side effect reported in official documents is oral discomfort or a tingling sensation. Official administration conditions indicate that the lozenge is intended to be moved around the mouth while sucking. This condition is in place to help prevent the local irritation that can sometimes cause discomfort.

Q: Does Strefen also have a numbing or anesthetic property?

The drug is classified as an NSAID with analgesic (pain-relieving) and anti-inflammatory effects. Its primary mechanism of action is to reduce the production of chemical mediators that cause inflammation and pain, rather than acting as a primary surface anesthetic.

Q: Can Strefen affect blood pressure levels?

Official regulatory warnings advise that Flurbiprofen, like other non-steroidal anti-inflammatory drugs (NSAIDs), may cause fluid retention and has the potential to increase blood pressure. This is why caution is advised for people with a history of hypertension.

Q: Does Strefen lozenge contain sugar or is it sugar-free?

According to the official regulatory product composition, Strefen lozenges are available in sugar-free formulations.

Q: Does having diabetes affect eligibility for Strefen use?

Official health information indicates that the use of NSAIDs in patients with conditions like diabetes requires a professional review of the condition and any concurrent medications. This allows for a proper assessment of the drug's appropriateness.

Q: Can Strefen be used while driving or operating machinery?

Regulatory product information lists central nervous system side effects such as dizziness, headache, and somnolence (sleepiness) as possibilities. Due to the possibility of these effects, the product label includes a general caution against driving or operating machinery until the user's reaction to the product is known.

Q: What happens if someone accidentally swallows a whole Strefen lozenge?

In the event of a significant overdose, regulatory documents list symptoms that may occur, including nausea, vomiting, stomach pain, or severe headache. If symptoms of discomfort or overdose occur, professional medical intervention may be necessary.

Q: Are there known long-term side effects of Strefen use? / Are there recent studies on Strefen's safety for prolonged use?

Official regulatory documents specify that this product is strictly indicated for short-term use only, for a maximum period of three days. The safety profile is based on clinical data from this short duration, and prolonged use is not authorized.

Q: Can I use Strefen if I am on medication for anxiety or depression?

Caution is advised when combining NSAIDs with certain medicines that affect the central nervous system, such as those used for anxiety or depression. The official documents also report that nervousness and anxiety have been known to occur as side effects of the active ingredient.

Storage and Disposal Requirements

Official regulatory documents define specific, non-advisory conditions for storing Strefen (flurbiprofen) lozenges to ensure product stability and safety.

Requirement Type	Official Labeled Instruction
Temperature	Do not store above 25 C (Controlled Room Temperature).
Environmental Protection	Must be stored in the original package to protect from light and moisture.
Child Safety	Keep the medicine out of the sight and reach of children.
Disposal	Do not dispose of via wastewater or with regular household waste.

All unused or expired lozenges and waste material must be discarded in accordance with local requirements, such as taking them to a pharmacy or using established drug take-back programs. These mandates prohibit disposal into the environment via common waste streams.